No Data
No Data
Hunan Warrant Pharmaceutical Completes Phase 1 Study for Antidepressant
Warner Pharmaceutical Factory (688799.SH): Subsidiary ZG-001 Capsule completes Phase I clinical trial and signs a cooperation framework agreement.
On September 30, Gracell announced that its holding subsidiary, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has recently completed Phase I clinical trials for project ZG-001 capsules under the approval of the National Medical Products Administration. Zhigen Pharmaceutical and Peking University Affiliated An Ding Hospital (referred to as "An Ding Hospital") have signed a "Cooperation Framework Agreement" for joint development of the ZG-001 project on the mainland of China. ZG-001 capsules are a new type of antidepressant with a completely new structure independently developed by Zhigen Pharmaceutical, classified as a class 1 new drug. ZG-001 is intended for the treatment of adult depression.
Does Hunan Warrant PharmaceuticalLtd (SHSE:688799) Have A Healthy Balance Sheet?
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Warner Pharmaceutical Factory (688799.SH): The net income in the first half of the year is approximately 0.113 billion yuan, a year-on-year increase of 0.52%.
Glory August 30th | Warner Pharmaceutical Factory (688799.SH) announced that the revenue in the first half of 2024 was approximately 739 million yuan, an increase of 2.43% year-on-year; net income attributable to shareholders of the listed company was approximately 113 million yuan, an increase of 0.52% year-on-year; basic earnings per share was 1.2 yuan.
No Data
No Data